Paladin in distribution pact with BTG

Paladin Labs (TSX:PLB) has entered into a distribution agreement with Protherics, a unit of BTG PLC, for the exclusive Canadian rights to market and sell DigiFab, which is under Health Canada review to treat life-threatening or potentially life-threatening digoxin toxicity or overdose.

“DigiFab provides an important opportunity to grow Paladin’s specialty and orphan franchise, which includes Replagal, Elaprase and Antizol,” CEO Jonathan Goodman said in a statement.  ”Following approval, DigiFab will provide patients and physicians with a new option for the treatment digoxin poisoning.”